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Abstract  
Human life expectancy is influenced by multiple determinants, including various environmental and 
genetic factors. Though the non-genetic factors are important, it is estimated that approximately 25–
32% of the overall difference in human lifespan for survival after the age of 60 years depends on for 
by genetic polymorphisms among individuals. In addition, there are human homologues to many 
genes that affect lifespan in model organisms. In people, longevity genes might slow the rate of age-
related changes in cells, increase resistance to environmental stresses like infection and injury, and 
reduce the risk of many age-related conditions. The best studied longevity pathway is probably the 
one involving insulin/IGF-1 signaling. The important role of IGF and insulin-related signaling 
pathways in the control of longevity of worms and insects is very well documented. In the mouse, 
2 
 
several spontaneous or experimentally induced mutations that interfere with GH/IGF axis 
modulation lead to extended longevity. Increases in the average life span in these mutants range 
from approximately 20–70% depending on the nature of the endocrine defect, gender, diet, and/or 
genetic background. All the data in animals models and in the population studies support the 
evidence that this pathway drives an evolutionarily conserved network that regulates lifespan and 
affects longevity across species. Results obtained in humans are still controversial and further 
extensive studies are required to firmly establish a role of the IGF1 axis in modulation of human 
longevity. A better knowledge of the role of this pathway in humans may assist in the design of 
improved treatment methods for age-related diseases, delay the aging process and prolong the 
human lifespan. 
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Introduction 
Longevity is determined by a mix of genetic, environmental, and chance elements. Several studies 
are currently being made to identify the genetically determined pathways and mechanisms of 
healthy longevity in humans, because these might provide targets for specific interventions aimed at 
preservation of disease-free longevity. Of the genetically determined pathways that have been 
implicated in longevity in model organisms, in current literature the best studied pathway is the 
insulin and insulin-like growth factor-1 (IGF-1) signaling (IIS) pathway. This pathway was 
originally identified in C. elegans1, 2, where it has been studied to the greatest extent. Several work, 
points to evolutionary conservation of this pathway in fruit flies 3 and mice 4,5   making this an 
important therapeutic target for longevity modulation in humans6,7. 
The IGF/insulin system in lower species 
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Recent studies on model organisms have shown that the insulin/insulin-like growth factor-1 (IGF-1) 
signaling pathway (IIS) plays a significant role in the regulation of longevity and extension of life 
span 3, 5, 8-10. The important role of IGF and insulin-related signaling pathways in the control of 
longevity of worms and insects is very well documented. Many insulin/IGF-1-pathway mutations 
have been shown to influence lifespan in flies. In the mouse, genetic alterations that interfere with 
the GH/IGF axis or sensitivity to IGF-I lead to extended longevity. IIS is an important nutrient-
sensing pathway that coordinates processes such as development, fat metabolism, growth and 
reproductive maturation. As such, this pathway is a good candidate for regulating longevity in 
response to energy availability. In C. elegans, environmental unfavorable growth conditions (such 
as food deprivation and over-crowding) triggers an increase secretion of pheromones and the warm 
enters an alternative larval stage, known as the dauer, that can withstand adverse conditions for 
prolonged periods 11. This is consistent with the function of IIS pathway in worms, where it 
regulates a hibernation-like state, that can occur during development if resources are scarce 12. 
Animals in this dauer stage are very resistant to thermal 13 and oxidative stresses14 and are 
considerably long-lived. It is possible that the long lived C. elegans IIS mutants are activating and 
benefiting from the same protective mechanisms that allow dauers to live long, but without the 
hibernation phenotypes.  
Genetic regulation of  IGF/insulin-like signaling pathways  
The pathway involving insulin/IGF-1 signaling is evolutionarily conserved: mutations in many 
insulin and IGF-1-pathway genes extend the lifespan of lower species and in mammals.  Reduced 
function of this pathway is associated with prolonged lifespan in several species 15. Mutations in 
many other signaling elements in this pathway, for example age-1 and daf-16, also affect longevity. 
These same genes are involved in the response to oxidative stress 15 up regulating the heat shock 
proteins, as well as tumor suppression 16, 17. In the Drosophila, mutations of the daf-2 homologue 
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insulin receptor, or a loss-of-function mutation in a homologue of the insulin receptor substrate, 
increase lifespan 3, 18.  Mice with a fat-specific insulin receptor knockout (FIRKO) live about 20% 
longer than controls 4. Heterozygous knockout mice with deletion of the IGF-1 receptor appear to 
have longer lifespan, although the effect may be specific to females 5. Thus, decreased insulin 
signaling in certain tissues may extend life. In growth hormone receptor knockout mice, the 
decreased growth hormone and IGF-1 are responsible for increased life span 19. The function of the 
insulin/IGF-1 signaling pathway in these mice is also decreased 20. Thus, the signaling system may 
act in a similar way in these mice as in C. elegans: mutation may result in physiological 
homeostasis that favors longevity, and the Snell dwarf mutant conforms to the nematode longevity 
paradigm. Several rare mutations in the growth hormone receptor in humans are associated to short 
stature 21  but their effects on lifespan are uncertain. Bonafè 22 et al first demonstrated that free  
IGF-1 plasma levels and human longevity are coregulated by an overlapping set of genes, 
describing an association between a SNP in the IGF-1 receptor gene (a G to A substitution at codon 
1013) and human longevity. This SNP was also associated with lower circulating levels of IGF-1. 
There is considerable evidence to suggest that the genetic and endocrine mechanisms that influence 
aging and longevity in mice may play a similar role in other mammalian species, including the 
human. 
The influence of IGF/insulin system on human longevity. 
IGF-1 plays a number of important roles in the human body. It is involved in physiological 
processes such as growth, development, and metabolism23 and has been implicated as a factor in the 
development of common diseases 24.  Serum IGF1 levels seems to influence susceptibility to 
disease, and therefore longevity. It is well known that people with a high level of circulating IGF1 
are more susceptible to cancers, while a low level of circulating IGF1 is a risk factor for 
cardiovascular diseases, premature atherogenesis, and diabetes 25. Pathological increased IGF1 
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levels as seen in uncontrolled acromegaly are associated with a substantially reduced lifespan, 
diabetes and cardiac disease 26, 27. In contrast,  the study from the Framingham cohort has 
demonstrated the protective role of IGF1 on the risk of developing heart failure 28. The results on 
top levels athletes have suggested a positive association between IGF1 levels and cardiac 
contractility assessed by echocardiography 29. Suh et al.7 recently studied IGF system in a cohort of 
Ashkenazi Jewish centenarians, their offspring, and offspring-matched controls. Female 
centenarians’ offspring showed higher serum IGF-I levels and shorter stature than controls. In this 
study genetic alterations in the human IGF1R that result in altered IGF signaling pathway confer an 
increase in susceptibility to human longevity. Data used from the Longitudinal Aging Study 
Amsterdam (LASA), an ongoing multidisciplinary cohort study in the general Dutch population of 
older persons (65 yrs. old) demonstrated an increased risk of all causes of mortality for older 
persons with IGF-I values in the lowest quintile as compared to the middle quintile [hazard ratio 
(HR), 1.28; 95% confidence interval (CI), 1.01–1.63]. A more than 2-fold increased risk of CVD 
mortality was revealed for both low-normal (HR, 2.39; 95% CI, 1.22–4.66) and high-normal (HR, 
2.03; 95% CI, 1.02–4.06) IGF-I values 30. Significant associations of serum IGF-I with nonfatal 
CVD and fatal and nonfatal cancer were not observed. In the Leiden population study intron 4 A/T 
SNP of GH1 was significantly associated with female longevity (relative mortality risk = 0.8) 31.  
Bonafè et al22 carried out a cohort study that enrolled a total of 496 healthy Italian subjects, 
including 278 young people (76 males and 202 females; mean age 54.8 years) and 218 long-lived 
people (56 males and 162 females; mean age 98.0 years). The results demonstrated that lower free 
IGF1 plasma levels were more frequently found in individuals carrying at least an A allele at 
insulin-like growth factor 1 receptor, IGF1R (AG and AA genotypes) than in GG genotype subjects. 
The study of insulin/IGF-1 signaling and FOXO (DAF-16) proteins in ageing has been recently 
explored and new link to human longevity was suggested.  Impaired IGF-1 receptor activity has 
been associated to exceptional longevity in Ashkenazi Jews, and FOXO DNA variants have been 
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correlated in Hawaiians centenarians of Japanese descent, Germans, Italians Californians, New 
Englanders, Ashkenazi Jews and the Chinese. Recently Pawlikowska et al. 32, genotyped 291 
common variants in 30 genes encoding proteins in the IIS signaling pathway in the 293 long-lived 
cases (age older than 92 years, mean age 95.3 years), and 603 younger controls (age less than 79 
years, mean age 75.7 years) selected from the SOF cohort. They demonstrated a modest excess of 
variants associated with human lifespan. Then, the genotyping was replicated in the two additional 
cohorts and a meta-analysis was performed across the three cohorts. They showed that an intronic 
SNP (rs3803304) in AKT1 was significantly associated with lifespan (OR = 0.78, adjusted p = 
0.043).  
In elderly population insulin sensitivity declines with age, consequently to a reduction in lean tissue, 
despite a decrease in BMI. Paolisso33 et al. previously reported that healthy centenarians have 
glucose tolerance and insulin action better than individuals aged >75 years and not different from 
those aged about 50 years. Centenarians had preserved insulin sensitivity, comparable with that of 
healthy young subjects. In fact, there is increasing evidence that IGF-I plays an important 
contributory role in the modulation of glucose metabolism. Higher bioactive IGF-I levels are 
reported in the less insulin sensitive subjects 34.  
Conclusions 
Despite the well-established role of the GH/IGF axis in modulation of lifespan in laboratory 
animals, its role in human longevity has been controversial. Moreover, human aging is associated 
with a decline in the levels of GH and IGFI, and it has been proposed that GH therapy may reverse 
some of the physiological features of aging 35. Therefore, at the current time, the role of IGF 
signaling in human longevity is far from clear. Previous reports have shown that the offspring of 
centenarians have a moderately lower prevalence of metabolic syndrome than their partners 36. 
Moreover, it has been reported that centenarians had preserved insulin sensitivity, comparable with 
that of healthy young subjects 33.  Additional comprehensive studies in the centenarians and their 
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offspring may reveal other molecules within the GH/IGF pathway that are operative in human 
longevity. Comprehensive analysis of all genes within this axis will be required to firmly establish a 
role of the IGFI axis in modulation of human longevity. So far, the best studied longevity patwhway 
involves insulin/IGF-1 signaling and supports the notion that the insulin/IGF-1 pathway drives an 
evolutionarily conserved network that regulates lifespan and affects longevity across species. 
 
Riassunto 
L’aspettativa di vita è influenzata da molteplici fattori, genetici e ambientali. Benché i fattori 
ambientali siano importanti, si ritiene che circa il 25-32% della sopravvivenza nell’uomo sopra i 60 
anni dipenda dalla differente presenza di polimorfismi genetici tra i singoli individui. 
Nei modelli animali vi sono omologhi umani che condizionano la durata della vita. Nell’uomo i 
geni che influenzano la longevità rallentano i cambiamenti cellulari età-correlati, aumentano la 
resistenza allo stress e alle infezioni e riducono il rischio di contrarre patologie età-correlate. Il 
sistema meglio studiato che influenza la longevità è forse quello dell’insulina/IGF-1. Nei vermi e 
negli insetti il ruolo di questo sistema correlato alla longevità è stato ben documentato. Nel topo 
molte varianti genetiche spontanee o sperimentali che interferiscono con la modulazione dell’asse 
GH/IGF causano un prolungamento della vite. In questi mutanti la vita media aumenta del 20-70%, 
secondo la natura del deficit endocrino, della dieta e/o dal background genetico. Tutti i dati nei 
modelli animali e negli studi di popolazione supportano l’evidenza che questo sistema fa parte di 
una reta conservata nell’evoluzione che regola la durata della vita e condiziona la longevità delle 
specie. 
I risultati ottenuti nell’uomo sono controversi e sono necessari studi più ampi e completi per 
stabilire definitivamente il ruolo dell’asse IGF1 nella modulazione della longevità. Una più 
approfondita conoscenza del ruolo di questo sistema nell’uomo potrà condurre a migliori possibilità 
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terapeutiche per le malattie età-correlate allo scopo di ritardare il processo di invecchiamento e 
prolungare l’aspettativa di vita nell’uomo.  
Parole chiave: longevità, insulina/IGF-1, genetica. 
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